We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Vical is scrapping development of its lead cancer drug candidate Allovectin after a pivotal Phase III trial failed to meet primary and secondary efficacy endpoints.